Interim 18F-FDG PET in hodgkin lymphoma: Would PET-adapted clinical trials lead to a paradigm shift?

Journal of Nuclear Medicine

Volumn 54, Issue 7, 2013, Pages 1082-1093

  Kostakoglu, Lale ^a   Gallamini, Andrea ^b  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

Author keywords

Clinical trials; Hodgkin lymphoma; Interim PET; PET CT response

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; HODGKIN DISEASE; HUMAN; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; OBSERVATIONAL STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; UNSPECIFIED SIDE EFFECT; EVIDENCE BASED MEDICINE; INTERIM PET; METHODOLOGY; PET/CT RESPONSE; SCINTISCANNING; TREATMENT OUTCOME;

CLINICAL TRIALS; HODGKIN LYMPHOMA; INTERIM PET; PET/CT RESPONSE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 84879919355     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.120451     Document Type: Article

References (70)

1. Canellos GP, Niedzwiecki D. Long term follow-up of Hodgkin's disease trial. N Engl J Med. 2002;346:1417-1418.
2. Bonadonna G, Viviani S, Bonfante V, Gianni AM, Valagussa P. Survival in Hodgkin's disease patients: report of 25 years of experience at the Milan Cancer Institute. Eur J Cancer. 2005;41:998-1006.
3. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998;339:1506-1514.
4. Tubiana M, Henry-Amar M, Carde P, et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987. Blood. 1989;73:47-56.
5. Josting A, Diehl V. Current treatment strategies in early stage Hodgkin's disease. Curr Treat Options Oncol. 2003;4:297-305.
6. Hoppe RT, Advani RH, Ai WZ, et al. Hodgkin lymphoma. J Natl Compr Canc Netw. 2011;9:1020-1058.
7. Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol. 2005;16:1160-1168.
8. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107:52-59.
9. Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica. 2006;91: 475-481.
10. Kostakoglu L, Goldsmith SJ, Leonard JP, et al. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer. 2006;107:2678-2687.
11. Zinzani PL, Tani M, Fanti S, et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. Ann Oncol. 2006;17:1296-1300.
12. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy- D glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25:3746-3752.
13. Zinzani PL, Rigacci L, Stefoni V, et al. Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients. Eur J Nucl Med Mol Imaging. 2012; 39:4-12.
14. Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol. 2009;27:1906-1914.
15. Connors JM. Positron emission tomography in the management of Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2011:317-322.
16. Josting A, Wiedenmann S, Franklin J, et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2003; 21:3440-3446.
17. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al. Long-term cause specific mortality of patients treated for Hodgkin's disease. J Clin Oncol. 2003;21:3431-3439.
18. Ng AK, Bernardo MP, Weller E, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol. 2002;20:2101-2108.
19. Sieniawski M, Reineke T, Nogova L, et al. Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Blood. 2008;111:71-76.
20. Engert A, Plütschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010;363:640-652.
21. Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23:4634-4642.
22. Spaepen K, Stroobants S, Dupont P, et al. [18F]FDG PET monitoring of tumour response to chemotherapy: does [18F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging. 2003;30:682-688.
23. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of International Harmonization Project in lymphoma. J Clin Oncol. 2007; 25:571-578.
24. André MPE, Reman O, Federico M, et al. First report on the H10 randomized intergroup trial on early FDG-PET scan guided treatment adaptation versus standard combined modality treatment in patients with supra-diaphragmatic stage I/II Hodgkin's lymphoma, for GELA, EORTC and IIL [abstract]. Blood. 2009;114(suppl):97.
25. Puccini B, Rigacci L, Zinzani PL, et al. Early positive FDG-PET scan do not confirm its prognostic impact in localized bulky disease Hodgkin lymphoma patients [abstract]. Haematologica. 2011;96(suppl):S3.
26. Gallamini A, Rossi A, Patti C, et al. Early treatment intensification in advanced-stage high-risk Hodgkin lymphoma (HL) patients, with a positive FDG-PET scan after two ABVD courses - first interim analysis of the GITIL/FIL HD0607 clinical trial. 54th ASH Annual Meeting and Exposition Web site. https://ash.confex.com/ash/2012/webprogram/Paper47545.html. Accessed May 31, 2013.
27. Shankar LK, Hoffman JM, Bacharach S, et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med. 2006;47:1059-1066.
28. Barrington SF, Qian W, Somer EJ, et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2010;37:1824-1833.
29. Gallamini A, O'Doherthy M. Report of satellite workshop on interim-PET in Hodgkin lymphoma: 8th International Symposium on Hodgkin Lymphoma, Cologne, 23 October 2010. Leuk Lymphoma. 2011;52:583-586.
30. Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma. 2009;50:1257-1260.
31. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579-586.
32. Juweid ME, Wiseman GA, Vose JM, et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop criteria (IWC) and 18F-fluorodeoxyglucose positron emission tomography (PET). J Clin Oncol. 2005;23:4652-4661.
33. Le Roux PY, Gastinne T, Le Gouill S, et al. Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria. Eur J Nucl Med Mol Imaging. 2011;38:1064-1071.
34. Gallamini A, Barrington S, Biggi A, Chauvie S, Gregianin M, Hutchings M, et al. International validation study of interpretation rules and prognostic role of interim-PET scan in advanced-stage Hodgkin lymphoma. Ann Oncol. 2011;22 (suppl 4):abstract O47.
35. Biggi A, Gallamini A, Chauvie S, et al. International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. J Nucl Med. March 20, 2013 [Epub ahead of print].
36. Kostakoglu L, Schoder H, Johnson J, et al. Interim FDG PET imaging in stage I/II non-bulky Hodgkin lymphoma: would using combined PET and CT criteria better predict response than each test alone? Leuk Lymphoma. 2012;53:2143-2150.
37. Diehl V, Re D, Harris NL, Mauch PM. Hodgkin lymphoma. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008:2167-2213.
38. Hatt M, Cheze le Rest C, Descourt P, et al. Accurate automatic delineation of heterogeneous functional volumes in positron emission tomography for oncology applications. Int J Radiat Oncol Biol Phys. 2010;77:301-308.
39. Werner-Wasik M, Nelson AD, Choi W, et al. What is the best way to contour lung tumors on PET scans? Multiobserver validation of a gradient-based method using a NSCLC digital PET phantom. Int J Radiat Oncol Biol Phys. 2012;82: 1164-1171.
40. Kostakoglu L, Gandikota N, Hutching M, et al. Deauville criteria and post-one cycle SUVmax decrease seems to predict progression free survival better than metabolic tumor measurements in classical Hodgkin's lymphoma [abstract]. Eur J Nucl Med Mol Imaging. 2012;39(suppl):S155.
41. Straus DJ, Johnson JL, LaCasce AS, et al. Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood. 2011;117:5314-5320.
42. Cerci JJ, Pracchia LF, Linardi CC, et al. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. J Nucl Med. 2010;51:1337-1343.
43. Barnes JA, LaCasce AS, Zukotynski K, et al. End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma. Ann Oncol. 2011;22:910-915.
44. Filippi AR, Botticella A, Bellò M, et al. Interim positron emission tomography and clinical outcome in patients with early stage Hodgkin lymphoma treated with combined modality therapy. Leuk Lymphoma. 2013;54:1183-1187.
45. Sher DJ, Mauch PM, Van Den Abbeele A, LaCasce AS, Czerminski J, Ng AK. Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy. Ann Oncol. 2009;20: 1848-1853.
46. Gallamini A, Patti C, Viviani S, et al. Gruppo Italiano Terapie Innovative nei Linfomi (GITIL). Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. Br J Haematol. 2011;152:551-560.
47. Markova J, Kahraman D, Kobe C, et al. Role of [18F]-fluoro-2-deoxy-D- glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone. Leuk Lymphoma. 2012;53:64-70.
48. Dann EJ, Blumenfeld Z, Bar-Shalom R, et al. A 10-year experience with treatment of high and standard risk Hodgkin disease: six cycles of tailored BEACOPP, with interim scintigraphy, are effective and female fertility is preserved. Am J Hematol. 2012;87:32-36.
49. Avigdor A, Bulvik S, Levi I, et al. Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma. Ann Oncol. 2010;21: 126-132.
50. Ziakas PD, Poulou LS. Improving outcome after positive interim PET in advanced Hodgkin's disease: reality vs expectation. Eur J Nucl Med Mol Imaging. 2008;35:1573-1575.
51. Kasamon YL. Prognostication and risk-adapted therapy of Hodgkin's lymphoma using positron emission tomography. Adv Hematol. 2011:271595.
52. Fludeoxyglucose F 18 PET scan-guided therapy or standard therapy in treating patients with previously untreated stage I or II Hodgkin's lymphoma (EORTC/GELA). Clinicaltrials.gov Web site. http://clinicaltrials.gov/ct2/show/ NCT00433433. Accessed May 31, 2013.
53. HD16 for early stage Hodgkin lymphoma. Clinicaltrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT00736320. Accessed May 31, 2013.
54. PET scan in planning treatment in patients undergoing combination chemotherapy for stage IA or stage IIA Hodgkin lymphoma. Clinicaltrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT00943423. Accessed May 31, 2013.
55. Response-based therapy assessed by PET scan in treating patients with bulky stage I and stage II classical Hodgkin lymphoma (CALGB 50801). Clinicaltrials. gov Web site. http://www.clinicaltrials.gov/ct2/show/ NCT01118026. Accessed May 31, 2013.
56. Chemotherapy based on PET scan in treating patients with stage I or stage II Hodgkin lymphoma (ECOG). Clinicaltrials.gov Web site. http://www. clinicaltrials. gov/ct2/show/NCT01390584. Accessed May 31, 2013.
57. Chemotherapy based on positron emission tomography scan in treating patients with stage I or stage II Hodgkin lymphoma (CALGB 50604). Clinicaltrials.gov Web site. http://www.clinicaltrials.gov/ct2/show/NCT01132807. Accessed May 31, 2013.
58. Tailored therapy for Hodgkin lymphoma using early interim therapy PET for therapy decision. Clinicaltrials.gov Web site. http://www.clinicaltrials.gov/ ct2/show/NCT00392314. Accessed May 31, 2013.
59. Study of a treatment driven by early PET response to a treatment not monitored by early PET in patients with AA stage 3-4 or 2B HL (AHL 2011). Clinicaltrials. gov Web site. http://clinicaltrials.gov/ct2/show/NCT01358747. Accessed May 31, 2013.
60. HD18 for advanced stages in Hodgkin lymphoma. Clinicaltrials.gov Web site. http://www.clinicaltrials.gov/ct2/show/NCT00515554. Accessed May 31, 2013.
61. Positron emission tomography (PET)-adapted chemotherapy in advanced Hodgkin lymphoma (HL) (HD0607). Clinicaltrials.gov Web site. http://www.clinicaltrials. gov/ct2/show/NCT00795613. Accessed May 31, 2013.
62. Fludeoxyglucose F 18-PET/CT imaging in assessing response to chemotherapy in patients with newly diagnosed stage II, stage III, or stage IV Hodgkin lymphoma (RATHL). Clinicaltrials.gov Web site. http://www.clinicaltrials.gov/ ct2/show/NCT00678327. Accessed May 31, 2013.
63. Fludeoxyglucose F 18-PET/CT imaging and combination chemotherapy with or without additional chemotherapy and G-CSF in treating patients with stage III or stage IV Hodgkin lymphoma (SWOG-CALG-B). Clinicaltrials. gov Web site. http://clinicaltrials.gov/ct2/show/NCT00822120. Accessed May 31, 2013.
64. High-dose chemotherapy and stem cell transplantation, in patients PET-2 positive, after 2 courses of ABVD (HD0801) and comparison of RT versus no RT in PET-2 negative patients (HD0802). Clinicaltrials.gov Web site. http://www.clinicaltrials.gov/ct2/show/NCT00784537. Accessed May 31, 2013.
65. HD17 for intermediate stage Hodgkin lymphoma. Clinicaltrials.gov Web site. http://www.clinicaltrials.gov/ct2/show/NCT01356680. Accessed May 31, 2013.
66. Radford J, O'Doherty M, Barrington S, et al. UK NCRI RAPID trial in patients with clinical stage IA/IIA Hodgkin lymphoma: an update following attainment of the recruitment target [Abstract 107]. International Working Group on Interim PET in Lymphoma Web site. http://eitti.free.fr/2011/2011.Posters. pdf. Accessed May 31, 2013.
67. Johnson PWM, Sydes MR, Hancock BW, et al. Consolidation radiotherapy in patients with advanced Hodgkin's lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519). J Clin Oncol. 2010;28: 3352-3359.
68. Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009;27:4548-4554.
69. Gallamini A, Marchetti M, Borra A, Sorasio R, Fiore F: Cost-effectiveness of interim PET response adapted therapy in ABVD-treated, advanced-stage Hodgkin lymphoma [abstract]. Blood 2011;118(suppl):1563.
70. Strobel K, Schaefer NG, Renner C, et al. Cost-effective therapy remission assessment in lymphoma patients using 2-[fluorine-18]fluoro-2-deoxy- D-glucose-positron emission tomography/computed tomography: is an end of treatment exam necessary in all patients? Ann Oncol. 2007;18:658-664.